Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 14, Issue 2, 2015, Pages 262-266

  Yau, Yvonne C W ^a   Ratjen, Felix ^a   Tullis, Elizabeth ^b,h   Wilcox, Pearce ^c   Freitag, Andreas ^d   Chilvers, Mark ^e   Grasemann, Hartmut ^a   Zlosnik, James ^f   Speert, David ^f   Corey, Mary ^g   Stanojevic, Sanja ^a   Matukas, Larissa ^b   Leahy, Timothy Ronan ^a   Shih, Sarah ^a   Waters, Valerie ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e BC CHILDREN S HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^h ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antibiotics; Biofilm; Pseudomonas aeruginosa; Pulmonary exacerbation

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BIOFILM; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SPUTUM; TREATMENT DURATION; CANADA; CHILD; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; LUNG FUNCTION TEST; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; PSEUDOMONAS INFECTIONS; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BIOFILMS; CANADA; CHILD; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME;

EID: 84924225296     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.09.013     Document Type: Article

References (15)

1. Waters V., Stanojevic S., Atenafu E.G., Lu A., Yau Y., Tullis E., et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012, 40(1):61-66.
2. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123(5):1495-1502.
3. Gaillard J.L., Cahen P., Delacourt C., Silly C., Le Bourgeois M., Coustere C., et al. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 1995, 14(4):291-296.
4. Aaron S.D., Vandemheen K.L., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005, 366(9484):463-471.
5. Singh P.K., Schaefer A.L., Parsek M.R., Moninger T.O., Welsh M.J., Greenberg E.P. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407(6805):762-764.
6. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2(1):29-34.
7. Quittner A.L., Buu A., Messer M.A., Modi A.C., Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005, 128(4):2347-2354.
8. Quittner A.L., Modi A.C., Wainwright C., Otto K., Kirihara J., Montgomery A.B. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009, 135(6):1610-1618.
9. Moskowitz S.M., Emerson J.C., McNamara S., Shell R.D., Orenstein D.M., Rosenbluth D., et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol 2011, 46(2):184-192.
10. Keays T., Ferris W., Vandemheen K.L., Chan F., Yeung S.W., Mah T.F., et al. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations. J Cyst Fibros 2009, 8(2):122-127.
11. Staudinger B.J., Muller J.F., Halldorsson S., Boles B., Angermeyer A., Nguyen D., et al. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014, 189(7):812-824.
12. Yu Q., Griffin E.F., Moreau-Marquis S., Schwartzman J.D., Stanton B.A., O'Toole G.A. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother 2012, 67(11):2673-2681.
13. Zhao J., Schloss P.D., Kalikin L.M., Carmody L.A., Foster B.K., Petrosino J.F., et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 2012, 109(15):5809-5814. [PMCID: 3326496].
14. Maughan H., Wang P.W., Diaz Caballero J., Fung P., Gong Y., Donaldson S.L., et al. Analysis of the cystic fibrosis lung microbiota via serial Illumina sequencing of bacterial 16S rRNA hypervariable regions. PLoS One 2012, 7(10):e45791.
15. VanDevanter D.R., Ballmann M., Flume P.A. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med 2011, 105(Suppl. 2):S18-S23.